TY - JOUR T1 - SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage JF - medRxiv DO - 10.1101/2020.12.28.20248906 SP - 2020.12.28.20248906 AU - Frederic Grabowski AU - Grzegorz Preibisch AU - Marek Kochańczyk AU - Tomasz Lipniacki Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/04/2020.12.28.20248906.abstract N2 - The novel SARS-CoV-2 Variant Under Investigation VUI-202012/01 (also known as B.1.1.7), first collected on September 20, 2020, in Kent, is a rapidly growing lineage that in the first half of December 2020 constitutes more than 1/3 of all SARS-CoV-2 genomes sequenced in England. Based on GISAID data we have shown nearly exponential growth of the VUI-202012/01 to non-VUI-202012/01 genomes ratio in the five-week period since October 19 till November 22, 2020, with weekly growth rate of 2.31 [95% CI: 2.08–2.57]. Assuming the serial interval of 6.73 days we estimated the replicative advantage of VUI-202012/01 lineage as 2.316.73/7 = 2.24 [95% CI: 2.03–2.48]. Such significant replicative advantage and the fact that London serves as major international transportation hub suggest that the VUI-202012/01 strain will likely become globally dominant, hindering containment of the COVID-19 epidemics prior to massive vaccinations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Science Centre (Poland) grant 2018/29/B/NZ2/00668.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This theoretical study is based on data published by GISAID and GOV.UKAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are referenced. GISAID: www.gisaid.org; UK.GOV: https://coronavirus.data.gov.uk/details/cases ER -